Pumping (IV) Iron Linked to Varying Anaphylaxis Risk for Old
Overall, 167,925 elderly patients were included in the analysis. The cohort averaged 77-79 years of age, and about two-thirds were women. A large majority (77%-86%) were white. The most common product received was iron sucrose (n=59,755) and ferumoxytol (n=40,778).

Users of iron sucrose and ferumoxytol had more chronic kidney disease, likely due to "differences in their approved indication for use." Anaphylactic reactions that required hospitalization were only seen among patients using iron dextran or ferumoxytol. Risk of either anaphylaxis or death was higher only for iron dextran (OR 3.2, 95% CI 1.9-5.3)

The highest adjusted incidence rates for anaphylaxis among Medicare recipients receiving IV iron was 9.8 cases (95% CI 6.2-15.3) per 10,000 first administrations of iron dextran (Dexferrum) and 4.0 (95% CI 2.5-6.6) cases per 10,000 for ferumoxytol (Feraheme). The rates of anaphylaxis were very low with all IV iron products but were 3- to 8-fold greater for iron dextran and ferumoxytol than for iron sucrose.

Source: https://www.acpjournals.org/doi/10.7326/M21-4009